Abstract
Emerging evidence suggests that novel COVID-19 is associated with increased prothrombotic state and risk of thromboembolic complications, particularly in severe disease. COVID-19 is known to predispose to both venous and arterial thrombotic disease. We describe a case of a 61-year-old woman with history of type II diabetes, hypertension and hyperlipidaemia who presented with dry cough and acute abdominal pain. She was found to have a significantly elevated D-dimer, prompting imaging that showed thrombi in her right ventricle and aorta. She had rapid clinical deterioration and eventually required tissue plasminogen activator with subsequent durable clinical improvement. This case highlights a rare co-occurrence of venous and arterial thrombi in a patient with severe COVID-19. Further studies are needed to clarify the molecular mechanism of COVID-19 coagulopathy, the utility of D-dimer to predict and stratify risk of thrombosis in COVID-19, and the use of fibrinolytic therapy in patients with COVID-19.
Keywords: COVID-19; haematology (incl blood transfusion); venous thromboembolism.
【저자키워드】 COVID-19, Venous Thromboembolism, haematology (incl blood transfusion), 【초록키워드】 therapy, thrombosis, severe COVID-19, risk, D-dimer, molecular mechanism, abdominal pain, hypertension, Venous Thromboembolism, Coagulopathy, Patient, Clinical improvement, utility, disease, predict, Blood, Evidence, Haematology, severe disease, Type II Diabetes, dry cough, fibrinolytic, thrombotic, thromboembolic complications, prothrombotic state, rapid clinical deterioration, venous, highlight, tissue plasminogen activator, significantly, subsequent, required, elevated, co-occurrence, patients with COVID-19, 【제목키워드】 severe COVID-19, Patient, ventricular,